Results 1 to 10 of about 3,401,781 (173)

Cytokine Release Syndrome (CRS) and Nicotine in COVID-19 Patients: Trying to Calm the Storm [PDF]

open access: yesFrontiers in Immunology, 2020
SARS-CoV-2 is a new coronavirus that has caused a worldwide pandemic. It causes severe acute respiratory syndrome (COVID-19), which is fatal in many cases, and is characterized by a cytokine release syndrome (CRS).
Jesus Gonzalez-Rubio   +6 more
doaj   +10 more sources

Effectiveness of Tocilizumab in a COVID-19 Patient with Cytokine Release Syndrome [PDF]

open access: yesEuropean Journal of Case Reports in Internal Medicine, 2020
Cytokine release syndrome (CRS) is a systemic inflammatory response that can be triggered by many factors such as infections. CRS in patients with coronavirus disease 2019 (COVID-19) is life-threatening and can occur very rapidly after COVID-19 diagnosis.
Sadettin Uslu
doaj   +2 more sources

Potential Pathophysiological Mechanisms Underlying Multiple Organ Dysfunction in Cytokine Release Syndrome

open access: yesMediators of Inflammation, 2022
In recent decades, many serious respiratory infections have broken out all over the world, including SARS-CoV, MERS, and COVID-19. They are characterized by strong infectivity, rapid disease progression, high mortality, and poor prognosis.
Peixian Chen   +6 more
doaj   +2 more sources

Cytokine release syndrome caused by immune checkpoint inhibitor: a case report [PDF]

open access: yesJichu yixue yu linchuang, 2022
Objective To investigate the diagnosis and treatment of cytokine release syndrome (CRS) caused by immune checkpoint inhibitor(ICI). Methods A case of ICI pembrolizumab leading to CRS was analyzed in Department of Pulmonary and Critical Care Medicine ...
SI Xiao-yan, WANG Han-ping, ZHANG Li, WANG Meng-zhao, ZHANG Xiao-tong
doaj   +2 more sources

Novel strategies for the mitigation of cytokine release syndrome induced by T cell engaging therapies with a focus on the use of kinase inhibitors

open access: yesOncoImmunology, 2022
T cell engaging therapies, like CAR-T cells and T cell engagers, redirect T cells toward tumor cells, facilitating the formation of a cytotoxic synapse and resulting in subsequent tumor cell killing. T cell receptor or CAR-T downstream signaling triggers
Gabrielle Leclercq   +5 more
doaj   +3 more sources

Interleukin Inhibitors in Cytokine Release Syndrome and Neurotoxicity Secondary to CAR-T Therapy

open access: yesDiseases, 2022
Introduction: Chimeric antigen receptor T-cell (CAR-T) therapy is an innovative therapeutic option for addressing certain recurrent or refractory hematological malignancies.
Puri Ferreros, Isabel Trapero
doaj   +2 more sources

Focused evaluation of the roles of macrophages in chimeric antigen receptor (CAR) T cell therapy associated cytokine release syndrome

open access: yesCancer Biology & Medicine, 2022
Cytokine release syndrome (CRS) is a major obstacle to the widespread clinical application of chimeric antigen receptor (CAR) T cell therapies. CRS can also be induced by infections (such as SARS-CoV-2), drugs (such as therapeutic antibodies), and some ...
Hanfei Guo, Lei Qian, Jiuwei Cui
doaj   +1 more source

Cervical Edema Extending to the Larynx as Local Cytokine Release Syndrome Following Chimeric Antigen Receptor T-Cell Therapy in a Boy with Refractory Acute Lymphoblastic Leukemia

open access: yesCase Reports in Oncology, 2022
Cytokine release syndrome (CRS) is one of the major acute complications caused by massive cytokine release after chimeric antigen receptor (CAR) T-cell therapy. Patients with tumor masses were considered at high risk of local CRS induced by the expansion
Haruko Shima   +7 more
doaj   +1 more source

Recent advances in the prevention and management of cytokine release syndrome after chimeric antigen receptor T-cell therapy

open access: yesEuropean Journal of Inflammation, 2022
Adoptive immunotherapy has recently garnered widespread interests owing to the successful application of chimeric antigen receptor T cell therapy.
Xiaoxue Shi, Hongfang Wu
doaj   +1 more source

Case Report: Local Cytokine Release Syndrome in an Acute Lymphoblastic Leukemia Patient After Treatment With Chimeric Antigen Receptor T-Cell Therapy: A Possible Model, Literature Review and Perspective

open access: yesFrontiers in Immunology, 2021
Chimeric antigen receptor T (CAR-T) cell therapy has achieved remarkable clinical efficacy in treatment of many malignancies especially for B-cell hematologic malignancies. However, the application of CAR-T cells is hampered by potentially adverse events,
Chengxin Luan   +10 more
doaj   +1 more source

Home - About - Disclaimer - Privacy